Navigation Links
Moffitt cancer center researchers find novel predictor for MDS progression risk
Date:9/12/2012

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

The study published in the August issue of The Journal of Immunology.

Awareness of the condition increased earlier this year when ABC's "Good Morning America" co-anchor Robin Roberts announced that she is battling MDS. Formerly known as pre-leukemia, MDS is a collection of blood disorders. One in three patients with MDS develops bone marrow failure and progresses to acute myelogenous leukemia within the first few years after diagnosis.

MDS involves the ineffective production of blood cells in bone marrow and often leaves patients anemic and in need of frequent blood transfusions.

The disease may develop as the result of chemotherapy or radiation for cancer treatment or can be related to bone marrow failure resulting from frequent transfusions and subsequent iron overload. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, a patient's organs can become overloaded with iron, leading to heart failure, liver injury, susceptibility to infection and other complications. Bone marrow transplantation may be necessary.

Seeking to understand more about the development of MDS, Moffitt researchers and their colleagues investigated aspects of the immune system, particularly the role of regulatory T cells, also known as Tregs. Tregs, said the researchers, are well-defined players in tumor immune invasion in solid tumors, but little is known about the role Tregs play in pre-malignant human diseases.

"We investigated a Treg subset called 'effector memory Tregs,' " said study senior author Pearlie K. Epling-Burnette, Pharm.D., Ph.D., senior member of Moffitt's Immunology Department. "We found that changes in the physical characteristics, or phenotypes, of Tregs in MDS suggest that they may be recently activated in a manner similar to effector memory T cells. By looking at a patient's effector memory Treg cells, we were able to identify patients at higher risk for MDS progression."

An increase in effector memory Tregs likely reflects active immune suppression and may represent the earliest biomarker indicating conversion to an immunosuppressive microenvironment, the researchers said.

The team concluded that the changes to effector memory Treg phenotype may also be a useful tool for identifying MDS patients who may respond to specific classes of drugs. This would make inclusion of a patient's Treg status into prognostic and treatment models potentially valuable for informing therapy decisions for patients with MDS.

"Our study sheds light on a unique aspect of T cells and immunity in a pre-malignant model of disease and specifically implicates the importance of changes to effector memory Tregs," concluded Epling-Burnette and her co-authors. "Our findings specifically implicate effector Treg expansion in disease progression in MDS."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers say race affect likelihood of finding suitable stem cell donor
2. Moffitt Cancer Center researchers study childhood melanoma characteristics
3. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
4. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
5. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
6. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
7. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
8. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
9. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
10. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
11. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... ... designs created specifically for use in Final Cut Pro X. The business-oriented elements ... productions. Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished look ...
(Date:5/21/2017)... ... ... Florida Pain Relief Group, a division of Physician Partners of America (PPOA), is ... Melbourne, on Monday, May 22. Initially the clinic will be supervised by Physician Partners ... 23 pain management clinics in Florida and the Dallas-Fort Worth, Texas metro area, and ...
(Date:5/21/2017)... Houston,Texas (PRWEB) , ... May 21, 2017 , ... ... but if it's been longer than six months since you've seen a dentist, ... dentist twice per year and getting x-rays once per year. , Dental checkups ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... in an upcoming episode of Innovations with Ed Begley, Jr., airing fourth quarter ... the distributor of a clean, organic dietary supplement made from naturally occurring ingredients. ...
(Date:5/19/2017)... CA (PRWEB) , ... May 19, 2017 , ... The ... consulting to families and entrepreneurs throughout the California Central Valley, is announcing a joint ... of raising community support for a local kid’s camp event. , The Boys and ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is teaming up with ... Limited to lower diabetes healthcare costs in ... which is available throughout all provinces and territories in ... eligible for additional savings when shopping for Dario supplies ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
Breaking Medicine Technology: